Menu
Anna Bosch, General Manager of EF CLIF, reflected on our achievements and milestones of the past year. Bosch emphasized the collaborative efforts and scientific progress that have significantly advanced the understanding and management of chronic liver disease.
Following this, Richard Moreau, Director of EF CLIF, introduced our new organizational structure. Moreau detailed how these changes aim to streamline research activities and enhance collaborative efforts across our network, ensuring more efficient and impactful research outcomes.
Next, Joan Clària, Head of Translational Operations at EF CLIF, presented ongoing research carried out under the umbrella of the Grifols Chair which complements the clinical studies carried out by the EASL-CLIF Consortium. Clària presented innovative omics approaches and breakthroughs in understanding the pathophysiology of chronic liver disease, emphasizing the potential for new therapeutic targets.
Javier Fernández, Head of Clinical Operations at EF CLIF, discussed most recent findings derived from ongoing clinical study, highlighting progress in the development of new protocols within two of our coordinated EU-funded projects, MICROB-PREDICT and DECISION. Fernández highlighted the importance of rigorous clinical trial design and expected impacts on patients outcomes.
Later, Thierry Gustot, Principal Investigator of the CHANCE study and Vice-Chair of the EASL-CLIF Consortium Steering Committee, shared recent findings from the CHANCE study. Interim results from this global observational study provide promissing evidence of the benefit of liver transplantation for patients with severe acute-on-chronic liver failure (ACLF).
Looking ahead, Paolo Angeli, Chair of the EASL-CLIF Consortium Steering Committee, outlined planned upcoming research initiatives. Angeli emphasized the Consortium’s commitment to pioneering new studies that will continue to push the boundaries of chronic liver disease research.
The EASL-CLIF Consortium General Assembly took place in Milan, Italy, on the occasion of the EASL Congress 2024. The event not only celebrated past achievements, but focused on future contributions to research and innovation, solidifying our role as a private, non-profit research foundation in the international arena.
European Foundation for the Study of
Chronic Liver Failure
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain
© European Foundation for the Study of Chronic Liver Failure 2024
